Evidence BriefsMembers1 view
Ruxolitinib in Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease — 3-Year Final Analysis of the Phase III REACH3 Study
Nanuli Gvazava
7 files
Ruxolitinib in Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease — 3-Year Final Analysis of the Phase III REACH3 Study
This material is available to GAIM members.
Become a member
Already a member? Log in
About this resource
Evidence Brief: “Ruxolitinib in Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease — 3-Year Final Analysis of the Phase III REACH3 Study” by ნანული გვაზავა, 15 July 2026. From the library of the Georgian Academy of Internal Medicine (GAIM); the full material is available to GAIM members.
Specialty
- Hematology
- Oncology
